Amylyx Pharmaceuticals Inc.

Home
United States
Cambridge, MA
Amylyx Pharmaceuticals Inc.

Ushering in a new era for treating diseases with high unmet needs

01/30/2026

Wolfram syndrome is a rare genetic disorder that affects approximately 3,000 people living in the U.S. with no approved treatment options.

Common manifestations of Wolfram syndrome include insulin-requiring diabetes mellitus, vision loss, diabetes insipidus, hearing loss, neurogenic bladder, impaired balance and coordination, and difficulty breathing that can progress to respiratory failure. Learn more about Wolfram syndrome on our website at: https://bit.ly/3Zbrhnf

01/26/2026

Our team is growing! Amylyx has an audacious mission to usher in a new era for treating diseases with high unmet needs. If you share our passion and are determined to tackle some of medicine’s toughest challenges, check out the opportunities here and apply: https://www.amylyx.com/open-positions

01/23/2026

Community voices drive innovation. To change the trajectory of diseases with high unmet needs, we first listen to those impacted.

Jessica is a passionate mother, case manager, and advocate with post-bariatric (PBH). She shared her story – and unwavering determination – with us to raise : https://amylyx.com/jessicas-PBH-story

If you’re interested in sharing your experience with PBH, email pbhcommunity@amylyx.com.

01/15/2026

Post-bariatric hypoglycemia (PBH) is a rare, chronic condition with no FDA-approved treatments. Among the roughly two million people who have had Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy in the past decade, an estimated 160,000 are living with PBH today.

The condition can cause debilitating low blood sugar episodes when the brain does not receive enough glucose. PBH can be difficult to diagnose as symptoms, such as brain fog, fatigue, sweating, blurred vision, and dizziness, can be non-specific, vary in severity, and/or be mistaken for dumping syndrome. Learn more about PBH on our website at https://www.amylyx.com/

01/08/2026

Today, we announced the nomination of an investigational, long-acting GLP-1 receptor antagonist as our new development candidate, identified in collaboration with Gubra A/S. Learn more about this exciting update: https://bit.ly/3LCCZEb

01/05/2026

We have an audacious mission to develop novel therapies for high unmet needs. Where others see challenges, we see opportunities that members of like Natalia pursue with urgency and unwavering commitment to the communities we serve.

View our open positions and apply today: https://www.amylyx.com/careers

12/23/2025

As 2025 comes to a close, our team took time to reflect on the milestones that shaped this year and the opportunities ahead in 2026.

To the incredible communities we work alongside: thank you for your trust and collaboration. Wishing you peace, joy, and a wonderful holiday season!

12/19/2025

Wolfram syndrome is a rare genetic disorder that affects multiple organs and systems over time.

Most people with Wolfram syndrome have mutations in the WFS1 gene, which encodes wolframin, a protein essential for maintaining endoplasmic reticulum (ER) homeostasis and normal cellular function.

When wolframin is impaired, cells experience chronic ER stress and mitochondrial dysfunction. Learn more about Wolfram syndrome on our website at https://www.amylyx.com/

12/17/2025

Post-bariatric hypoglycemia (PBH) places a heavy burden on those it affects, with sudden and unpredictable low blood sugar events that can cause severe symptoms like confusion, fainting, and seizures. These events can make daily activities – like working, driving, or even being alone – difficult or unsafe.

As we work toward developing a much-needed PBH treatment, Amylyx is also committed to supporting the community with education and resources. That’s why we developed the “Understanding PBH” guide in close collaboration with the PBH community. View and download here: https://bit.ly/4pL23aZ

12/11/2025

Maria and her family had big plans: travel adventure, and a new chapter after bariatric surgery. But post-bariatric hypoglycemia ( ) brought these dreams to a halt. In this clip, Maria and her daughter talk about the emotional toll of living with PBH and the need for treatment options.

Watch her full story here: https://bit.ly/4oQuNxA

12/10/2025

Amylyx cares deeply about supporting and investing in our people, and we’re thrilled that Tapan agrees. Hear what he shared about our company culture and find out more about our approach to learning and development: https://www.amylyx.com/careers

12/05/2025

Today, we announced we will proceed with cohort 2 enrollment in our LUMINA trial in following cohort 1 safety data demonstrating our investigational A*O was generally well-tolerated, with no treatment-related serious adverse events.

We look forward to presenting these data at the 36th International Symposium on ALS/MND. Learn more and see additional presentation details here: https://bit.ly/445x0Oo

Address

55 Cambridge Parkway, Suite 6W
Cambridge, MA
02142

Website

https://www.amylyx.com/, https://www.amylyx.com/social-media-guidelines, https://www.amylyx.com/privacy-notice

Alerts

Be the first to know and let us send you an email when Amylyx Pharmaceuticals Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Amylyx Pharmaceuticals Inc.:

Want your practice to be the top-listed Clinic in Cambridge?